Vico Medical Successfully Closes Series C Financing Round, Securing Hundreds of Millions in Funding to Propel Cardiovascular Innovation

VCBeat learned第一时间 that recently, Wuhan Vickor Medical Technology Co., Ltd. ("Vickor") officially announced that the company has successfully completed its C-round financing, with an amount reaching several hundred million RMB, led by a well-known investment institution in Liangxi District, Wuxi City.BocapitalFully led the investment. This round of financing will provide strong financial support for Vickor in product development, market expansion, and international strategic layout.

Since its establishment in July 2018, Vickor has consistently focused on addressing significant clinical needs within the cardiovascular field, particularly in the area of heart failure and minimally invasive interventions for structural heart disease. With core competencies in research and development, technical services, manufacturing, and sales, the company is committed to building an innovative medical device platform that provides comprehensive cardiovascular solutions throughout the entire patient care cycle, offering advanced products and treatment options to patients and doctors worldwide.

The medical device market in the cardiovascular field, both in China and globally, is in a phase of rapid development. The market scale is continuously expanding, with technological innovation and market expansion being the main trends, which has brought significant development opportunities for Vickor. In this context, Vickor, leveraging its outstanding R&D capabilities and market insight, has successfully launched multiple innovative products, gaining widespread recognition in the industry. This round of financing will further accelerate the development of new product lines, deepen market presence, and promote international progress, aiming to secure a position in the global market and contribute to improving the current state of cardiovascular disease treatment worldwide.

Currently, Vickor's product line covers multiple cardiovascular treatment areas, including atrial shunt devices and various active devices for heart failure prevention and treatment, patent foramen ovale closure devices for cardioembolic stroke prevention, transcatheter aortic valve replacement systems for treating valvular diseases, as well as related surgical accessory consumables.

It is worth mentioning that the PFO occluder and multiple配套耗材have been successfully commercialized.

Atrial Shunt Device Receives NMPA's "Special Review Procedure for Innovative Medical Devices" Certification and FDA's "Breakthrough Medical Device" Designation.

And independently developed a transcatheter aortic valve replacement system with world-class advanced technology, meeting the dual indications of both stenosis and regurgitation. The procedure does not require general anesthesia or pacemaker assistance, utilizes a minimally invasive interventional approach, and can be completed in just 40 minutes.

Bocapital Investment TeamIndicates:"Vickor's innovation capabilities and market performance in the cardiovascular medical device field are impressive. We believe that through the close cooperation and joint efforts of both parties, we will surely achieve more brilliant results in this field."

Vickor Medical Founder & Chairman Shang XiaokeStated: "We are highly honored to gain the recognition and support of Bohua Capital. This round of financing will bring us more resources and support, enabling us to further our efforts in the cardiovascular medical device field. With even greater determination and an innovative spirit, we will continue to advance medical technology and strive to provide patients with higher quality medical services."

Vickor Medical Co-Founder&CEO Wang XueliIndicates:"Vickor will continue to focus on the clinical needs in the cardiovascular field, particularly on minimally invasive interventional treatments for heart failure and structural heart disease. At the same time, we will strengthen cooperation with medical institutions, research organizations, and upstream and downstream industry partners to jointly build an innovative ecosystem in the cardiovascular healthcare sector, contributing to the sustainable development of the industry."

Vickor Medical Co-Founder&CTO Chen SongIndicates:"This round of financing not only provides us with financial security but also affirms Vickor's strategic direction. We will take this as an opportunity to increase R&D efforts, expand market channels, and accelerate internationalization."

The successful completion of Wuhan Vickor Medical Technology Co., Ltd.'s Series C financing round marks a further consolidation of its leading position in the cardiovascular medical device field. Looking ahead, we are full of anticipation, confident that Vickor Medical will unwaveringly take technological innovation as its core engine, continuously research and develop more outstanding medical products, contribute to the global cardiac health cause, and lead the industry toward an even brighter future!